Biocryst Pharmaceuticals (BCRX) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.04 Bn | 198.05 Bn | 7.24 Bn | 65.85% |
| 2 | Gilead Sciences | 181.35 Bn | 178.17 Bn | 6.22 Bn | -635.24% |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn | 6.48% |
| 4 | Regeneron Pharmaceuticals | 82.94 Bn | 74.94 Bn | 3.93 Bn | -6.81% |
| 5 | Argenx Se | 61.53 Bn | 56.34 Bn | 1.37 Bn | 92.37% |
| 6 | Moderna | 54.25 Bn | 49.11 Bn | 52.00 Mn | 5.21% |
| 7 | Alnylam Pharmaceuticals | 34.41 Bn | 31.10 Bn | 992.69 Mn | 327.74% |
| 8 | Biogen | 31.19 Bn | 29.91 Bn | 1.96 Bn | -84.64% |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | - |
| 10 | Biocryst Pharmaceuticals | 2.31 Bn | 1.95 Bn | 214.41 Mn | 1,441.69% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1,441.69% |
| Mar 31, 2026 | -2,255,762.50% |
| Dec 31, 2025 | 1,017.50% |
| Sep 30, 2025 | 191.92% |
| Jun 30, 2025 | 140.12% |
| Mar 31, 2025 | 100.09% |
| Dec 31, 2024 | 56.59% |
| Sep 30, 2024 | 61.18% |
| Jun 30, 2024 | 83.17% |
| Mar 31, 2024 | 33.66% |
| Dec 31, 2023 | 13.71% |
| Sep 30, 2023 | 14.98% |
| Jun 30, 2023 | -27.98% |
| Mar 31, 2023 | 28.12% |
| Dec 31, 2022 | -302.39% |
| Sep 30, 2022 | 27.69% |
| Jun 30, 2022 | -36.25% |
| Mar 31, 2022 | -15.42% |
| Dec 31, 2021 | 69.07% |
| Sep 30, 2021 | -27.54% |